PRA Health Sciences (PRAH) Tops Q2 EPS by 7c, Raises FY15 EPS Guidance

PRA Health Sciences (NASDAQ: PRAH) reported Q2 EPS of $0.47, $0.07 better than the analyst estimate of $0.40. Revenue for the quarter came in at $336.5 million versus the consensus estimate of $336.74 million.

PRA Health Sciences sees FY2015 EPS of $1.75-$1.85, versus prior guidance of $1.62-$1.72 and the consensus of $1.67. PRA Health Sciences sees FY2015 revenue of $1.34-1.39 billion, versus the consensus of $1.37 billion.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M